Cargando…

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

Chimeric antigen receptor (CAR) T cell immunotherapies have shown remarkable efficacy in treating multiple types of hematological malignancies but are not sufficiently effective at treating solid tumors. NKG2D is a strong activating receptor for NK cells and a co-stimulatory receptor for T cells. NK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ruocong, Cheng, Lin, Jiang, Zhiwu, Wei, Xinru, Li, Baiheng, Wu, Qiting, Wang, Suna, Lin, Simiao, Long, Youguo, Zhang, Xuchao, Wu, Yilong, Du, Xin, Pei, Duanqing, Liu, Pentao, Li, Yangqiu, Cui, Shuzhong, Yao, Yao, Li, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287795/ https://www.ncbi.nlm.nih.gov/pubmed/30546945 http://dx.doi.org/10.1080/2162402X.2018.1509173

Ejemplares similares

Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
por: Qin, Le, et al.
Publicado: (2017)

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
por: Qin, Le, et al.
Publicado: (2020)

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
por: Lv, Jiang, et al.
Publicado: (2019)

PSCA is a target of chimeric antigen receptor T cells in gastric cancer
por: Wu, Di, et al.
Publicado: (2020)

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
por: Zheng, Diwei, et al.
Publicado: (2022)

CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression
por: Lin, Shouheng, et al.
Publicado: (2017)

Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemia
por: Jiang, Zhiwu, et al.
Publicado: (2017)

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
por: Jiang, Zhiwu, et al.
Publicado: (2017)

Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized
por: Jiang, Zhiwu, et al.
Publicado: (2016)

CRISPR/Cas9-Mediated Deletion of Foxn1 in NOD/SCID/IL2rg(−/−) Mice Results in Severe Immunodeficiency
por: Wei, Xinru, et al.
Publicado: (2017)

Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis
por: Qin, Le, et al.
Publicado: (2022)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
por: Lin, Shouheng, et al.
Publicado: (2021)

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D
por: Li, Shanglin, et al.
Publicado: (2022)

Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments
por: Ye, Wei, et al.
Publicado: (2015)

GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways
por: Ye, Wei, et al.
Publicado: (2016)

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer
por: Zhao, Ruocong, et al.
Publicado: (2021)

Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells
por: Xiao, Yiren, et al.
Publicado: (2015)

Translational frameshifting in the Escherichia coli dnaX gene in vitro.
por: Tsuchihashi, Z
Publicado: (1991)

Engineered Ssp DnaX inteins for protein splicing with flanking proline residues
por: Zhang, Xiao, et al.
Publicado: (2019)

Human induced-T-to-natural killer cells have potent anti-tumour activities
por: Jiang, Zhiwu, et al.
Publicado: (2022)

Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels
por: Lv, Jiang, et al.
Publicado: (2022)

Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models
por: Elhai, Muriel, et al.
Publicado: (2015)

Structural probing and mutagenic analysis of the stem-loop required for Escherichia coli dnaX ribosomal frameshifting: programmed efficiency of 50%
por: Larsen, Bente, et al.
Publicado: (1997)

Borrelia burgdorferi DnaA and the Nucleoid-Associated Protein EbfC Coordinate Expression of the dnaX-ebfC Operon
por: Krusenstjerna, Andrew C., et al.
Publicado: (2022)

Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes
por: Li, Wei, et al.
Publicado: (2015)

Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
por: Lin, Zili, et al.
Publicado: (2021)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

Apoptosis of CD19(+) chimeric antigen receptor T cells after treatment with chemotherapeutic agents
por: Yi, Wenfang, et al.
Publicado: (2018)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Development of molecular and pharmacological switches for chimeric antigen receptor T cells
por: Wu, Bill X., et al.
Publicado: (2019)

New insights into antigen specific immunotherapy for chronic myeloid leukemia
por: Li, Yangqiu, et al.
Publicado: (2012)

A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
por: Lin, Zili, et al.
Publicado: (2021)

A brief review concerning Chimeric Antigen Receptors T cell therapy
por: Li, Ling-Lin, et al.
Publicado: (2020)

Chimeric antigen receptor T cells: a novel therapy for solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021
por: Ou, Zhanpeng, et al.
Publicado: (2022)

Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
por: Ren, Pei-pei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ecuht9ocsjjigjis5sdurglnea